vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and SMITH & WESSON BRANDS, INC. (SWBI). Click either name above to swap in a different company.

SMITH & WESSON BRANDS, INC. is the larger business by last-quarter revenue ($124.7M vs $77.6M, roughly 1.6× Bioceres Crop Solutions Corp.). SMITH & WESSON BRANDS, INC. runs the higher net margin — 1.5% vs -9.6%, a 11.1% gap on every dollar of revenue. On growth, SMITH & WESSON BRANDS, INC. posted the faster year-over-year revenue change (-3.9% vs -16.8%). Over the past eight quarters, SMITH & WESSON BRANDS, INC.'s revenue compounded faster (-4.8% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Smith & Wesson Brands, Inc. (S&W) is an American firearm manufacturer headquartered in Maryville, Tennessee, United States.

BIOX vs SWBI — Head-to-Head

Bigger by revenue
SWBI
SWBI
1.6× larger
SWBI
$124.7M
$77.6M
BIOX
Growing faster (revenue YoY)
SWBI
SWBI
+13.0% gap
SWBI
-3.9%
-16.8%
BIOX
Higher net margin
SWBI
SWBI
11.1% more per $
SWBI
1.5%
-9.6%
BIOX
Faster 2-yr revenue CAGR
SWBI
SWBI
Annualised
SWBI
-4.8%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q2 FY2026

Metric
BIOX
BIOX
SWBI
SWBI
Revenue
$77.6M
$124.7M
Net Profit
$-7.4M
$1.9M
Gross Margin
46.8%
24.3%
Operating Margin
9.3%
3.3%
Net Margin
-9.6%
1.5%
Revenue YoY
-16.8%
-3.9%
Net Profit YoY
-20.2%
-53.6%
EPS (diluted)
$-0.12
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
SWBI
SWBI
Q4 25
$124.7M
Q3 25
$77.6M
$85.1M
Q2 25
$140.8M
Q1 25
$60.6M
$115.9M
Q4 24
$98.8M
$129.7M
Q3 24
$93.3M
$88.3M
Q2 24
$159.1M
Q1 24
$84.0M
$137.5M
Net Profit
BIOX
BIOX
SWBI
SWBI
Q4 25
$1.9M
Q3 25
$-7.4M
$-3.4M
Q2 25
$8.6M
Q1 25
$-1.6M
$2.1M
Q4 24
$605.2K
$4.5M
Q3 24
$-6.2M
$-1.9M
Q2 24
$27.9M
Q1 24
$9.8M
$7.9M
Gross Margin
BIOX
BIOX
SWBI
SWBI
Q4 25
24.3%
Q3 25
46.8%
25.9%
Q2 25
28.8%
Q1 25
39.4%
24.1%
Q4 24
42.0%
26.6%
Q3 24
40.2%
27.4%
Q2 24
35.5%
Q1 24
50.8%
28.7%
Operating Margin
BIOX
BIOX
SWBI
SWBI
Q4 25
3.3%
Q3 25
9.3%
-3.5%
Q2 25
9.3%
Q1 25
1.5%
4.1%
Q4 24
14.5%
5.8%
Q3 24
2.5%
-1.7%
Q2 24
17.4%
Q1 24
15.7%
8.2%
Net Margin
BIOX
BIOX
SWBI
SWBI
Q4 25
1.5%
Q3 25
-9.6%
-4.0%
Q2 25
6.1%
Q1 25
-2.6%
1.8%
Q4 24
0.6%
3.5%
Q3 24
-6.6%
-2.1%
Q2 24
17.5%
Q1 24
11.6%
5.7%
EPS (diluted)
BIOX
BIOX
SWBI
SWBI
Q4 25
$0.04
Q3 25
$-0.12
$-0.08
Q2 25
$0.19
Q1 25
$-0.02
$0.05
Q4 24
$0.00
$0.10
Q3 24
$-0.10
$-0.04
Q2 24
$0.60
Q1 24
$0.14
$0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
SWBI
SWBI
Cash + ST InvestmentsLiquidity on hand
$15.5M
$22.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$363.2M
Total Assets
$734.9M
$548.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
SWBI
SWBI
Q4 25
$22.4M
Q3 25
$15.5M
$18.0M
Q2 25
$25.2M
Q1 25
$38.5M
$26.7M
Q4 24
$29.2M
$39.1M
Q3 24
$32.3M
$35.5M
Q2 24
$60.8M
Q1 24
$16.4M
$47.4M
Stockholders' Equity
BIOX
BIOX
SWBI
SWBI
Q4 25
$363.2M
Q3 25
$288.3M
$364.4M
Q2 25
$372.5M
Q1 25
$345.0M
$366.9M
Q4 24
$346.3M
$371.5M
Q3 24
$346.0M
$380.0M
Q2 24
$399.9M
Q1 24
$348.5M
$376.4M
Total Assets
BIOX
BIOX
SWBI
SWBI
Q4 25
$548.6M
Q3 25
$734.9M
$554.6M
Q2 25
$559.6M
Q1 25
$798.2M
$578.9M
Q4 24
$835.2M
$587.4M
Q3 24
$827.3M
$571.3M
Q2 24
$577.4M
Q1 24
$836.1M
$570.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
SWBI
SWBI
Operating Cash FlowLast quarter
$14.4M
$27.3M
Free Cash FlowOCF − Capex
$16.3M
FCF MarginFCF / Revenue
13.1%
Capex IntensityCapex / Revenue
8.8%
Cash ConversionOCF / Net Profit
14.22×
TTM Free Cash FlowTrailing 4 quarters
$21.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
SWBI
SWBI
Q4 25
$27.3M
Q3 25
$14.4M
$-8.1M
Q2 25
$40.8M
Q1 25
$23.3M
$-9.8M
Q4 24
$-5.4M
$-7.4M
Q3 24
$5.2M
$-30.8M
Q2 24
$43.7M
Q1 24
$-17.4M
$25.2M
Free Cash Flow
BIOX
BIOX
SWBI
SWBI
Q4 25
$16.3M
Q3 25
$-12.4M
Q2 25
$33.5M
Q1 25
$-16.1M
Q4 24
$-10.7M
Q3 24
$-35.5M
Q2 24
$38.2M
Q1 24
$7.0M
FCF Margin
BIOX
BIOX
SWBI
SWBI
Q4 25
13.1%
Q3 25
-14.6%
Q2 25
23.8%
Q1 25
-13.9%
Q4 24
-8.3%
Q3 24
-40.2%
Q2 24
24.0%
Q1 24
5.1%
Capex Intensity
BIOX
BIOX
SWBI
SWBI
Q4 25
8.8%
Q3 25
5.0%
Q2 25
5.2%
Q1 25
5.4%
Q4 24
2.5%
Q3 24
5.3%
Q2 24
3.5%
Q1 24
13.2%
Cash Conversion
BIOX
BIOX
SWBI
SWBI
Q4 25
14.22×
Q3 25
Q2 25
4.73×
Q1 25
-4.68×
Q4 24
-8.85×
-1.63×
Q3 24
Q2 24
1.57×
Q1 24
-1.78×
3.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons